Furthermore, cancer cells harbouring CCNE1 gene amplification displayed a higher sensitivity to the CDK1, CDK2 and CDK9 small molecule inhibitor AZD5438 [56,57] than cancer cells lacking CCNE1 gene amplification (t-test, P = 0.019, Figure 5D). The gene discussed is CDK2; the disease is cancer.